| MONDAY,
Oct. 14 (HealthScoutNews) -- A natural compound often used as an antioxidant
is showing promise in slowing the progression of Parkinson's disease.
Researchers in 10 hospitals across the United States tested the compound,
called coenzyme Q10, in 80 patients who were in the
early stages of Parkinson's.
After 16 months, the study found patients taking the highest dose of
coenzyme Q10 had 44 percent less decline in their ability to carry out
activities of daily living, including dressing, bathing and walking.
However, doctors caution it's too soon to recommend coenzyme Q10 to
patients with Parkinson's.
"While it is tremendously encouraging that our results indicate that it
is likely that coenzyme Q10 slows the progression of Parkinson's disease,
our study did not have sufficient numbers of patients to unequivocally prove
that it does," says Dr. Clifford Shults, the study's principal investigator
and a professor of neurosciences at the University of California, San Diego.
"It would be premature to recommend that patients with Parkinson's disease
take high doses of coenzyme Q10."
Dr. Joel Perlmutter, a Parkinson's expert and professor of neurology,
radiology and neurobiology at Washington University in St. Louis, made that
point even more strongly.
"My father has Parkinson's, and I'm telling him not to take it," says
Perlmutter, whose hospital was one of the centers involved with the study.
"The findings are suggestive but not conclusive. Larger studies may
demonstrate an unexpected result. There could be an adverse effect, although
we haven't seen any evidence of that yet."
Coenzyme Q10 is classified as a dietary supplement and is therefore not
regulated by the U.S. Food and Drug Administration. It's sold in various
forms, including as a toothpaste additive, at health food stores.
However, the versions of the coenzyme Q10 sold in stores may differ and
might not contain beneficial amounts of the compound, Shults says.
Furthermore, it's very costly, he adds.
Another consideration: The people in the study had early-stage
Parkinson's. None of the patients were taking any other Parkinson's
medication, and nothing says coenzyme Q10 is beneficial for people with
later stages of Parkinson's, he says.
The study appears in tomorrow's issue of the Archives of Neurology,
and the researchers made a presentation today at the annual meeting of the
American Neurological Association in New York City.
Parkinson's is a degenerative brain disease that affects about 1 percent
of Americans over age 65. Symptoms include tremors, slowness of movement and
muscle stiffness to the point of paralysis. Some patients also develop
problems with sleeping, swallowing, depression and a decline in mental
function.
Certain drugs, including levodopa, can reduce symptoms of Parkinson's
disease, but no drug has been shown to slow the progressive deterioration in
function.
The exact cause of Parkinson's in unknown, although it results from a
loss of brain cells that produce the neurotransmitter dopamine.
What does coenzyme Q10 have to do with it?
Coenzyme Q10 is a molecular compound found in the mitochondria, a long,
oval-shaped part of cells that convert nutrients into energy. Coenzyme Q10
is also a potent antioxidant.
Previous research by Shults and his colleagues has shown that people with
Parkinson's have low levels of coenzyme Q10 and that the function of
mitochondria is impaired.
In the current study, 80 patients were randomly assigned to one of four
groups: those taking four doses of coenzyme Q10 that added up to 300, 600,
or 1,200 milligrams a day, and those taking a placebo.
Study participants had a thorough physical exam and medical history taken
before taking the coenzyme Q10.
They were then re-examined at regular intervals for up to 16 months, or
until it was determined they needed to begin taking medication such as
levodopa for the treatment of symptoms.
The eight-month exam was when the differences between the groups really
began to show. Those on the highest dosage of coenzyme Q10 showed fewer
declines in their physical abilities, mental function and mood. Those taking
lower doses of coenzyme Q10 didn't do as well, but they did better than
those on the placebo.
The benefit was seen throughout the 16 months of the study.
Shults believes coenzyme Q10 was doing more than just relieving the
symptoms. If that was the case, he says, the groups taking the coenzyme Q10
would have shown improvement at the first check-up, one month into the
study.
Since it wasn't until eight months into the study that the differences in
the groups became apparent, Shults believes the coenzyme Q10 could be
stopping Parkinson's march. "It suggests it may be possible to actually slow
the progression of the disease rather than just treat the symptoms," he
says.
Researchers are now seeking funding for a larger clinical trial to study
the effects of dosages of 1,200 milligrams a day of coenzyme Q10 and
greater.
"The value of this study is to lay the foundation for a subsequent larger
study," Perlmutter says. "It's exciting. I'm enthusiastic about doing a real
trial now to really find out if this stuff has benefit. It's a big step, but
it's not the final step."
What To Do
To read more about Parkinson's disease, visit the
Parkinson's Disease Foundation or the
National
Institutes of Health. |
